UK Column was recently able to interview top French vaccine expert Professor Christian Perronne on the subject of Covid-19 vaccines.
Professor Perronne is Head of the Medical Department at Raymond Poincaré Hospital in Garches, the teaching hospital for the University of Versailles-St Quentin near Paris. He was the University's Head of Department for Infectious and Tropical Diseases from 1994 onwards, but was fired from that position a few months ago. He is a Fellow of France's biomedical research centre of world standing, the Institut Pasteur, from which he graduated in bacteriology and virology and where he served as Deputy Director of the National Reference Centre for Tuberculosis and Mycobacteria until 1998.
He has chaired many top-level health committees, including the French Specialist Committee for Communicable Diseases, and the High Council on Public Health (French acronym: HCSP), which advises the government on public health policy and vaccination policy. He is not anti-vaccine and indeed wrote France's vaccination policy for many years, as well as presiding over the National Consultation Group on Vaccination, also known as the Technical Committee on Vaccination (CTV).
Professor Perronne was also the Vice-President of the European Advisory Group to the World Health Organisation. At national level in France, he has chaired the Infectious and Tropical Diseases Teaching College (CMIT), the Infectious Diseases Federation (FFI, which he co-founded), the High Council for Public Hygiene (CSHP), and the National Medical and Healthcare products Safety Agency (ANSM, previously AFSSAPS), which evaluates the health risks of medicines and is France's sole regulator of biomedical research. Until 2013, he sat on the Scientific Council of the French Microbiology and Infectious Diseases Research Institute (IMMI/INSERM).
Despite Professor Perronne's extensive knowledge and experience of communicable diseases, vaccines and vaccine policy at national and governmental level in France, he was quickly censored for speaking out on the subject of Covid-19 vaccines, their claimed efficacy and their identifiable risks. In short, he was professionally sidelined, his reputation was attacked and his professional opinions were censored.
Please see quote from Anne-Marie Yim from transcript. See also benign 3minute video about Graphene on toast, clothing and cardboard having tasty potential. Surprised it hasn't been pulled.
Anne-Marie Yim:
"One of the main [phenomena] being reported is the magnetic test at the site of vaccination: it sticks. People have been measuring these, and there’s an electromagnetic field that is engineered.
[the lipid nanoparticles used to deliver Covid-19 vaccines] have three components: basically, first, phospholipids (a fat), cholesterol and but it also contains a [ferric oxide] pegylation [polymer attachment]of graphene oxide which is inserted into the phospholipid layer.
And that goes into your brain. It can cross the blood-brain barrier. Normally, it shouldn’t, but it can go and pass into your brain.
And there is also this graphene oxide. Basically, everything about this injection is poisonous: not just this messenger RNA and these spike proteins, which cause inflammations and which can be integrated into [your] DNA, but also the graphene oxide. So clearly, from every point of view, this is a poison."
Perhaps the biggest Wuhan coronavirus (Covid-19) threat right now are people who took the “vaccines,” suggests Prof. Christian Perronne, a former head at the World Health Organization’s (WHO) European Advisory Group of Experts in Immunization.
Perronne warned in a recent speech that “fully vaccinated” people must quarantine over the winter months or else risk becoming seriously ill or even dying, now that their immune systems have been permanently altered with experimental gene therapy.
A specialist in tropical pathologies and emerging infectious diseases, Perronne says the situation in Israel and the United Kingdom, two of the most highly vaccinated countries in the world, is deteriorating rapidly. The same is expected to occur here in the United States as well.
“Unvaccinated people are not dangerous; vaccinated people are dangerous for others,” Perronne is quoted as saying.
“It’s proven in Israel now – I’m in contact with many physicians in Israel – they’re having big problems, severe cases in the hospitals are among vaccinated people, and in U.K. also, you have the larger vaccination program and also there are problems.”
A working group in France is said to be “utterly panicked” about the situation and not sure what to do to address it. Most of the people getting sick after testing “positive” for the Wuhan coronavirus (Covid-19) are people who took the jabs, which is not what we were all told would happen as part of “Operation Warp Speed.”
“95% of seriously ill patients are vaccinated. Fully vaccinated people account for 85-90% of hospitalizations,” announced an Israeli doctor by the name of Kobi Haviv during a segment on Channel 13 News.
“We are opening more and more covid branches. The effectiveness of vaccines is declining or disappearing.”
If the effectiveness of covid vaccines is “disappearing,” then why the aggressive push for more of them?
The European Union is quickly procuring more and more drugs to combat the corona virus... including Immunosuppressive agents ( agents that decreases the body's immune responses, reducing the body's ability to fight infections and other diseases, such as cancer.)
Plus Monoclonal antibodies (mAbs) that are produced by introducing an antigen to a mouse and then fusing polyclonal B cells from the mouse's spleen to myeloma cells. The resulting hybridoma cells are cultured and continue to produce antibodies to the antigen. (EWE)?!!
Do you know what is in these monoclonal antibodies? Do your research. The Magic Mice of Regeneron
Based on the predictions of Dr. Zaks, who oversaw the creation of the vaccine now being given to millions of people worldwide, the same Big Pharma companies that could potentially give people cancer with one vaccine could step forward later with another vaccine offering the cure for cancer. If you are the CEO of a mega pharmaceutical who answers to profit-driven Wall Street shareholders, that’s a brilliant strategy!
To them stupid and unethical is brilliant and bundeled with $$$.
The EU's COVID-19 treatment strategy is yielding first results today, with the announcement of the first portfolio of five treatments that may soon be available to treat patients across the EU .
Health and Food Safety Commissioner Stella Kyriakides said: “Today we are taking the first step towards establishing a broad portfolio of COVID-19 treatments. Although vaccination is progressing at an increasing rate, the virus is not going to go away and patients will need safe and effective treatments to reduce the pressure of COVID-19. Our goal is clear: to identify other pioneering candidates under development and to authorize at least three new treatments by the end of the year. This is the European Health Union. ”
The five products are at an advanced stage of development and have a good chance of being among the three new treatments for COVID-19 that will be authorized by October 2021 - the target set as part of the strategy - however that the final data demonstrate their safety, quality and efficacy. These are the following products: a new indication for COVID-19 for existing drugs:
Eli Lilly's immunosuppressant baricitinib (a medicine that reduces the activity of the immune system): an application for the extension of the marketing authorization to include the indication for COVID-19 is pending 'exam; newly developed monoclonal antibodies undergoing continuous evaluation - a regulatory tool to accelerate the evaluation of a promising drug in the event of a public health emergency: the combination of bamlanivimab and etesevimab by Eli Lilly: continuous assessment; the combination of casirivimab and imdevimab from Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd: ongoing evaluation; Celltrion's regdanvimab: ongoing evaluation; sotrovimab from GlaxoSmithKline and Vir Biotechnology, Inc .: ongoing evaluation.
Next steps The Commission will develop a portfolio of at least 10 potential COVID-19 treatments by October, building on the work of the recently established COVID-19 Variants Expert Group.
The selection process will be objective and science-based, with the selection criteria agreed with the Member States. Since different types of products are needed for different patient populations and different stages and degrees of disease severity, the expert group will establish product categories and select the most promising treatment candidates for each category, based on the basis of scientific criteria. The portfolio will contribute to the goal of having at least three new treatments authorized by October and possibly two more by the end of the year.
The European Medicines Agency will launch further ongoing evaluations of promising treatments by the end of 2021, based on research and development results. The Commission recently concluded a joint procurement agreement for the acquisition of monoclonal antibodies (casirivimab and imdevimab) and could launch further proceedings by the end of the year. The first industry matchmaking event for treatments will be held on July 12-13 to ensure that once approved, treatments are produced in sufficient quantity, as quickly as possible. context
The EU's COVID-19 treatment strategy aims to build a broad portfolio of COVID-19 treatments with the aim of having three new treatments by October 2021 and possibly two more by the end of the year. It encompasses the entire life cycle of drugs, from research, development, selection of promising candidates, their rapid regulatory approval, manufacture and deployment to end use. The strategy is part of the strengthening of a European Health Union, which is based on a coordinated EU approach to better protect the health of our citizens, the aim being to empower the EU and to its Member States the means to better prevent future pandemics, to cope with them and to improve the resilience of European health systems. This strategy, which focuses on the treatment of patients with COVID-19, is a continuation of the EU's proven vaccine strategy,
(The only thing thats been proven is that the vaccines maim an kill more than covid, is this your proven strategy)?
Whereby the use of safe and effective COVID-19 vaccines has been authorized in the EU to prevent and reduce the transmission of cases, as well as hospitalization and death rates from the disease.
Margaritis Schinas, Vice-President for Promotion of Our European Way of Life, said: “The situation in many intensive care units remains critical across Europe. We need to focus on both vaccines and treatments, two powerful and complementary ways to fight COVID-19. Currently, however, we only have one drug authorized to treat COVID-19. By acting today on a better availability of drugs, we ensure that patients benefit from the treatments they need, while strengthening our future biomedical preparation. A coordinated strategy for rapid access to treatment will strengthen our strategic autonomy and help strengthen a Health Union. ”
Health and Food Safety Commissioner Stella Kyriakides said: “Vaccinations save lives, but they cannot eradicate COVID-19 yet. We need to make major efforts in the area of treatment to limit the need for hospitalization, speed up recovery times and reduce mortality. We want to ensure that patients in Europe and around the world have access to world-class drugs against COVID-19. This is why we have set a very clear goal: by October, we will develop and authorize three new effective treatments for COVID-19 that can change the course of the disease. To do this, we will invest in research and innovation, the identification of promising new drugs, the strengthening of production capacities and support for equitable access. Our treatment strategy is an expression of the strengthening of a European Health Union. ”
Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, said: “By improving the availability of vaccines across Europe, an increasing number of Europeans are now protected against COVID-19. In the meantime, developing innovative drugs to treat coronavirus patients remains a priority when it comes to saving lives. Research and innovation are the first step towards finding effective and safe treatments, which is why we are proposing to create a new COVID-19 “treatment innovation booster”, in which we will invest 90 million dollars. 'euros in demographic studies and clinical trials. " context The COVID-19 treatment strategy complements the European Union's June 2020 strategy for COVID-19 vaccines and builds on the ongoing work of the European Medicines Agency and Commission to support research, development, manufacture and deployment of treatments.
The strategy is part of the strengthening of a European Health Union, which is based on a coordinated EU approach to better protect the health of our citizens, the aim being to empower the EU and to its Member States the means to better prevent future pandemics, to cope with them and to improve the resilience of European health systems.
Today, the Commission is proposing immediate action to prepare Europe for the increased threat of coronavirus variants. The new European bio-defence preparedness planagainst COVID-19 variants called “HERA Incubator” will work with researchers, biotech companies, manufacturers and public authorities in the EU and globally to detect new variants, provide incentives to develop new and adapted vaccines, speed up the approval process for these vaccines, and ensure scaling up of manufacturing capacities.
Taking action now is important as new variants continue to emerge and challenges with scaling up vaccine production are arising. The HERA Incubator will also serve as a blueprint for the EU's long‑term preparedness for health emergencies.
Key actions to boost preparedness, develop vaccines for the variants and increase industrial production:
Detect, analyse and assess variants
Developing specialised tests for new variants, and to support genomic sequencing in Member States with at least €75 million in EU funding;
Reaching the target of 5% of genome sequencing of positive tests to help identify variants, monitor their spread in populations, and screen their impact on transmissibility;
Stepping up research and data exchange on variants with €150 million funding;
Launching the VACCELERATE COVID-19 clinical trial network, bringing together 16 EU Member States and five associated countries including Switzerland and Israel to exchange data and progressively also include children and young adults as participants in clinical trials.
Speed up regulatory approval ofadapted vaccines: based on the annual influenza vaccine model, the EU will provide accelerated approval for adapted COVID-19 vaccines by:
Adapting the regulatory framework, such as amending the regulatory procedure to enable the approval of an adapted vaccine with a smaller set of additional data submitted to EMA on a rolling basis;
Providing guidance on data requirements for developers from the European Medicines Agency so that the requirements for variants are known in advance;
Facilitating certification of new or repurposed manufacturing sites through early involvement of regulatory authorities;
Considering a new category of emergency authorisation of vaccines at EU level with shared liability among Member States.
Ramp up production of COVID-19 vaccines: the EU will:
Update or conclude new Advance Purchase Agreements to support the development of new and adapted vaccines through EU funding, with a detailed and credible plan showing capability to produce vaccines in the EU, on a reliable timescale. This should not prevent the EU from considering sources from outside the EU if needed, provided they meet the EU safety requirements;
Work closely with manufacturers to help monitoring supply chains and addressing identified production bottlenecks;
Support the manufacturing of additional vaccines addressing new variants;
Develop a voluntary dedicated licensing mechanism to facilitate technology transfer;
Support cooperation between undertakings;
Ensure the EU's manufacturing capacity by building up the “EU FAB” project.
The actions announced today will go hand-in-hand with global cooperation via the World Health Organisation and global initiatives on vaccines. They will also prepare the ground for the European Health Emergency Preparedness and Response Authority (HERA). HERA will build on the actions launched today and provide a permanent structure for risk modelling, global surveillance, technology transfers, manufacturing capacity, supply chain risk mapping, flexible manufacturing capacity and vaccine and medicine research and development.
Members of the College said:
President of the European Commission, Ursula von der Leyen , said: “Our priority is to ensure that all Europeans have access to safe and effective COVID-19 vaccines as soon as possible. At the same time, new variants of the virus are emerging fast and we must adapt our response even faster. To stay ahead of the curve, we are launching today the HERA Incubator. It brings together science, industry and public authorities, and pulls all available resources to enable us to respond to this challenge.”
Margaritis Schinas , Vice-President of the European Commission, said: “In our fight against the virus we are anticipating problems and acting proactively to mobilise all means to address the impact of variants. With our new bio-defence preparedness plan ‘HERA Incubator', we are tackling parallel or subsequent series of pandemics deriving from the variants. Today's proposal is the perfect example of what the EU is best at: pooling efforts and complementing them by funding. This is the way to get out from the crisis, ready to adapt to new circumstances and united in action - ensuring solidarity across the EU and the world.”
Stella Kyriakides, Commissioner for Health and Food Safety, said*:* “Europe is determined to stay ahead of the threat of new coronavirus variants. The HERA Incubator is an exercise in foresight, anticipation and united response. We can meet the dual challenge of addressing new variants and increasing our vaccine production capacity. It will build bridges between research, industry and regulators to speed up the processes - starting from the detection of variants all the way to the approval and production of vaccines. We need significant investments now and for the future and the HERA Incubator is a crucial part of our response.”**
Thierry Breton, Commissioner for the Internal Market, said: “The Task Force for ramping-up vaccine production is already engaging on a daily basis with industry to better address and anticipate potential bottlenecks. With this increased cooperation, we will ensure that the industrial phase of vaccine production allows manufacturers to meet their commitments while anticipating our future needs and adjusting vaccine production to future variants. Today, with HERA incubator, we are providing a strong structural response.This is not only about short term fixes: it will contribute to a higher level of autonomy in the area of health in the near future for our Continent.”
Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, said: “Research and innovation continue to be crucial in fighting the continuing challenges of this pandemic. The HERA Incubator and the reinforcement of European infrastructures and networks, supported by additional funding from Horizon 2020 and Horizon Europe programmes, will help us deal with any variants and be better prepared for future outbreaks.”
Background
The EU Vaccine Strategy has secured access to 2.6 billion vaccine doses as part of the broadest global portfolio of safe and secure COVID-19 vaccines. Less than a year since the virus appeared for the first time in Europe, vaccination has started across all Member States. This is a remarkable achievement of European and global advanced research and vaccine development, condensing what usually takes 5-10 years in just over 10 months.
At the same time, there are challenges to scale-up industrial vaccine production to keep pace. In order to boost production capacity in Europe, a much closer, more integrated and more strategic public-private cooperation with industry is needed. In this spirit, the Commission has set-up a Task Force for Industrial Scale-up of COVID-19 vaccines to detect and help respond to issues in real-time.
Europe now also needs to stay ahead of the curve as new and emerging threats continue to appear in the present or on the horizon. The most immediate of these are emerging and multiplying variants already spreading and developing in Europe and across the world. Presently, authorised vaccines are considered effective against the variants we are aware of. However, Europe must be ready and prepared for the possibility of future variants being more or fully resistant to existing vaccines.
